CBL0137, a metabolically stable curaxin, activates p53 (EC50: 0.37 μM) and inhibits NF-κB (EC50: 0.47 μM). It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death. CBL0137 has broad anticancer activity in mice when administered orally, eradicates drug-resistant cancer stem cells, and potentiates the efficacy of gemcitabine in preClinicalal models of pancreatic cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 114 | |
2 mg | In stock | $ 205 | |
4 mg | In stock | $ 328 | |
10 mg | In stock | $ 549 | |
20 mg | In stock | $ 878 |
Description | CBL0137, a metabolically stable curaxin, activates p53 (EC50: 0.37 μM) and inhibits NF-κB (EC50: 0.47 μM). It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death. CBL0137 has broad anticancer activity in mice when administered orally, eradicates drug-resistant cancer stem cells, and potentiates the efficacy of gemcitabine in preClinicalal models of pancreatic cancer. |
Targets&IC50 | NF-κB: 0.47 μM (EC50), p53: 0.37 μM (EC50) |
Synonyms | Curaxin 137, CBLC137 |
CAS No. | 1197996-80-7 |
Chemical Formula | C21H24N2O2 |
Molecular Weight | 336.435 |
Solubility | DMSO: ~5 mg/mL H2O: InsolubL; E |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom